Interplay Between Cellular Methyl Metabolism and Adaptive Efflux During Oncogenic Transformation from Chronic Arsenic Exposure in Human Cells

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2008 May 20

PMID 18487201

Citations 36

Authors

Jean-Francois Coppin

Wei Qu

Michael P Waalkes

Affiliations

Soon will be listed here.

Abstract

After protracted low level arsenic exposure, the normal human prostate epithelial cell line RWPE-1 acquires a malignant phenotype with DNA hypomethylation, indicative of disrupted methyl metabolism, and shows arsenic adaptation involving glutathione overproduction and enhanced arsenic efflux. Thus, the interplay between methyl and glutathione metabolism during this progressive arsenic adaptation was studied. Arsenic-treated cells showed a time-dependent increase in LC50 and a marked increase in homocysteine (Hcy) levels. A marked suppression of S-adenosylmethionine (SAM) levels occurred with decreased methionine adenosyltransferase 2A (converts methionine to SAM) expression and increased negative regulator methionine adenosyltransferase B, suggesting reduced conversion of Hcy to SAM. Consistent with Hcy overproduction, activity and expression of S-adenosylhomocysteine hydrolase (converts S-adenosylhomocysteine to Hcy) were both increased. Expression of cystathionine beta-synthase, a key gene in the transsulfuration pathway, and various glutathione production genes were increased, resulting in a 5-fold increase in glutathione. Arsenic efflux increased along with expression of ATP-binding cassette protein C1, which effluxes arsenic as a glutathione conjugate. Evidence of genomic DNA hypomethylation was observed during early arsenic exposure, indicating that the disruption in methyl metabolism had a potential impact related to oncogenesis. Thus, cellular arsenic adaptation is a dynamic, progressive process that involves decreased SAM recycling and concurrent accumulation of Hcy, which is channeled via transsulfuration to increase glutathione and enhance arsenic efflux but may also impact the carcinogenic process.

Citing Articles

Research progress on the regulatory mechanism of cell senescence in arsenic toxicity: a systematic review.

Gu Y, Qiu Y, Li Y, Wen W Toxicol Res (Camb). 2024; 13(4):tfae136.

PMID: 39184219 PMC: 11339171. DOI: 10.1093/toxres/tfae136.

Maternal arsenic exposure modifies associations between arsenic, folate and arsenic metabolism gene variants, and spina bifida risk: A case‒control study in Bangladesh.

Wei C, Tindula G, Mukherjee S, Wang X, Ekramullah S, Arman D Environ Res. 2024; 261:119714.

PMID: 39094898 PMC: 11460318. DOI: 10.1016/j.envres.2024.119714.

Maternal Exposure to Arsenic and Its Impact on Maternal and Fetal Health: A Review.

Ortiz-Garcia N, Cipriano Ramirez A, Juarez K, Brand Galindo J, Briceno G, Calderon Martinez E Cureus. 2023; 15(11):e49177.

PMID: 38130554 PMC: 10734558. DOI: 10.7759/cureus.49177.

DNA Methylation Aberrations in Dimethylarsinic Acid-Induced Bladder Carcinogenesis.

Yamamoto T, Gi M, Yamashita S, Suzuki S, Fujioka M, Vachiraarunwong A Cancers (Basel). 2023; 15(21).

PMID: 37958445 PMC: 10648661. DOI: 10.3390/cancers15215274.

Epigenomic reprogramming in iAs-mediated carcinogenesis.

George S, Cassidy R, Saintilnord W, Fondufe-Mittendorf Y Adv Pharmacol. 2023; 96:319-365.

PMID: 36858778 PMC: 10860658. DOI: 10.1016/bs.apha.2022.08.004.

References

Ueland P . Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev. 1982; 34(3):223-53. View

Chen H, Li S, Liu J, Diwan B, Barrett J, Waalkes M . Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis. 2004; 25(9):1779-86. DOI: 10.1093/carcin/bgh161. View

Glick J, Ross S, Leboy P . S-adenosylhomocysteine inhibition of three purified tRNA methyltransferases from rat liver. Nucleic Acids Res. 1975; 2(10):1639-51. PMC: 343534. DOI: 10.1093/nar/2.10.1639. View

Thomas D, Styblo M, Lin S . The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol. 2001; 176(2):127-44. DOI: 10.1006/taap.2001.9258. View

Crooks P, Tribe M, Pinney R . Inhibition of bacterial DNA cytosine-5-methyltransferase by S-adenosyl-L-homocysteine and some related compounds. J Pharm Pharmacol. 1984; 36(2):85-9. DOI: 10.1111/j.2042-7158.1984.tb02999.x. View

Xie Y, Liu J, Benbrahim-Tallaa L, Ward J, Logsdon D, Diwan B . Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology. 2007; 236(1-2):7-15. PMC: 2465467. DOI: 10.1016/j.tox.2007.03.021. View

Park E, Garrow T . Interaction between dietary methionine and methyl donor intake on rat liver betaine-homocysteine methyltransferase gene expression and organization of the human gene. J Biol Chem. 1999; 274(12):7816-24. DOI: 10.1074/jbc.274.12.7816. View

Bello D, Webber M, Kleinman H, Wartinger D, Rhim J . Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis. 1997; 18(6):1215-23. DOI: 10.1093/carcin/18.6.1215. View

Benbrahim-Tallaa L, Waterland R, Styblo M, Achanzar W, Webber M, Waalkes M . Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol. 2005; 206(3):288-98. DOI: 10.1016/j.taap.2004.11.017. View

10.

Webber M, Bello D, Kleinman H, Hoffman M . Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis. 1997; 18(6):1225-31. DOI: 10.1093/carcin/18.6.1225. View

11.

Gonzalgo M, Liang G, Spruck 3rd C, Zingg J, Rideout 3rd W, Jones P . Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 1997; 57(4):594-9. View

12.

Ramirez T, Garcia-Montalvo V, Wise C, Cea-Olivares R, Poirier L, Herrera L . S-adenosyl-L-methionine is able to reverse micronucleus formation induced by sodium arsenite and other cytoskeleton disrupting agents in cultured human cells. Mutat Res. 2003; 528(1-2):61-74. DOI: 10.1016/s0027-5107(03)00099-x. View

13.

Lertratanangkoon K, Orkiszewski R, Scimeca J . Methyl-donor deficiency due to chemically induced glutathione depletion. Cancer Res. 1996; 56(5):995-1005. View

14.

Welsh J, McClelland M . Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res. 1990; 18(24):7213-8. PMC: 332855. DOI: 10.1093/nar/18.24.7213. View

15.

Liu J, Chen H, Miller D, Saavedra J, Keefer L, Johnson D . Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol. 2001; 60(2):302-9. DOI: 10.1124/mol.60.2.302. View

16.

Benbrahim-Tallaa L, Waalkes M . Inorganic arsenic and human prostate cancer. Environ Health Perspect. 2008; 116(2):158-64. PMC: 2235216. DOI: 10.1289/ehp.10423. View

17.

Brambila E, Achanzar W, Qu W, Webber M, Waalkes M . Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase. Toxicol Appl Pharmacol. 2002; 183(2):99-107. View

18.

Yideng J, Jianzhong Z, Ying H, Juan S, Jinge Z, Shenglan W . Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol. 2007; 26(8):603-11. DOI: 10.1089/dna.2007.0584. View

19.

Lertratanangkoon K, Wu C, Savaraj N, Thomas M . Alterations of DNA methylation by glutathione depletion. Cancer Lett. 1998; 120(2):149-56. DOI: 10.1016/s0304-3835(97)00300-5. View

20.

Townsend D, Tew K, Tapiero H . The importance of glutathione in human disease. Biomed Pharmacother. 2003; 57(3-4):145-55. PMC: 6522248. DOI: 10.1016/s0753-3322(03)00043-x. View